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study question: Are the transmembrane mucins, MUC1, MUC4 and MUC16, differentially expressed in endometriosis compared with
normal endometrium?
summary answer: This study revealed that transmembrane mucin expression does not vary significantly in normal endometrium during
the menstrual cycle and is not altered in endometriosis relative to the epithelial marker, cytokeratin-18 (KRT18).
what is known already: Increased serum levels of the transmembrane mucin fragments MUC1, MUC4 and MUC16 that normally
dominate the apical surface of simple epithelia are found in several pathological conditions, including endometriosis. Altered mucin expression in
gynecologic diseases may promote infertility or endometrial pathologies.
study design, size, duration: This was a laboratory-based study of samples from 12 endometriosis patients as well as non-endo-
metriosis control samples obtained from 31 patients.
participants/materials, setting, methods: Total RNA was isolated from endometrial biopsies of ectopic and eutopic
endometrium from women with endometriosis and control patients from different stages of the menstrual cycle. Quantitative (q)-RT–PCR
analyses were performed for the mucins, MUC1, MUC4 and MUC16, relative to the epithelial marker, cytokeratin-18 (KRT18), or b-actin
(ACTB). Frozen sections from endometrial biopsies of proliferative and mid-secretory stage women with endometriosis were immunostained
for MUC1, MUC4 and MUC16.
main results and the role of chance: qRT–PCR analyses of MUC1 and MUC16 mRNA revealed that these mucins do not vary
significantly during the menstrual cycle nor are they altered in women with endometriosis relative to the epithelial marker, KRT18. MUC4 mRNA is
expressed at very low levels relative to MUC1 and MUC16 under all conditions. There was little difference in MUC1 and MUC16 expression
between eutopic endometrial and ectopic endometriotic tissues. MUC4 expression also was not significantly higher in the ectopic endometriotic
tissues. Immunostaining for all three mucins reveals robust expression of MUC1 and MUC16 at the apical surfaces of endometrial epithelia, but
little to no staining for MUC4.
limitations, reasons for caution: qRT–PCR analysis was the main method used for mucin detection. Additional studies with
stage III– IV endometriotic tissue would be useful to determine if changes in MUC1 and MUC16 expression occur, or if MUC4 expression
increases, at later stages of endometriosis.
wider implications of the findings: We report a comprehensive comparative profile of the major transmembrane mucins,
MUC1, MUC4 and MUC16, relative to the epithelial marker, KRT18, in normal cycling endometrium and in endometriosis, and indicate
constitutive expression. Previous studies have profiled the expression of individual mucins relative to b-actin and indicate accumulation in
the luteal phase. Thus, these differences in interpretation appear to reflect the increased epithelial content of endometrium during the
luteal phase.
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Introduction
The transmembrane mucins, MUC1, MUC4 and MUC16, belong to a
family of very large, heavily glycosylated proteins that are characterized
by a variable number of tandem repeat (VNTR) motifs. These mucins
are expressed on the apical surface of nearly all simple epithelial tissues
as well as various tumor cells and serve to keep epithelial surfaces lubri-
cated and hydrated, protecting them from pathogens and environmental
challenges (Hattrup and Gendler, 2008). Uterine membrane-tethered
mucins play a key role in embryo implantation, a process facilitated by
the loss or reduction of the mucin barrier (Braga and Gendler, 1993;
Brayman et al., 2004; Dharmaraj et al., 2009). Dysregulated mucin ex-
pression is associated with various disease states (Hollingsworth and
Swanson, 2004; Rose and Voynow, 2006; Vlad et al., 2006; Margarit
et al., 2010; Chang et al., 2011; He et al., 2011) and high levels of
transmembrane mucin expression reduce drug efficacy and protect
cells from apoptosis (Hollingsworth and Swanson, 2004; Ren et al.,
2004). Transmembrane mucin expression is hormonally regulated
during the estrous/menstrual cycle in manyspecies (Heyet al., 1994; Sur-
veyor et al., 1995; Hild-Petito et al., 1996; Hoffman et al., 1998; Julian
et al., 2005; Gipson et al., 2008) and altered expression of membrane-
tethered mucins is associated with infertility (Koscinski et al., 2006;
Margarit et al., 2010). In addition, increased serum levels of transmem-
brane mucin fragments are found in gynecological pathologies such as
endometrial cancer and endometriosis (He et al., 2011; Szubert et al.,
2012). Endometriosis is abenignchronic inflammatory disorderassociated
with an increased risk of progression to ovarian cancer and impaired fe-
cundity (Lessey et al., 2013). The Center for Disease Control reports
that 11.8% of all women (17 million in the USA alone) between the
ages of 15 and 44 have endometriosis. Identifying approaches to control
transmembrane mucin expression provides novel opportunities to
enhance embryo implantation success, improve protective functions of
the female reproductive tract and potentially reduce endometriotic
spread and/or enhance the efficacy of existing therapies.
MUC1 expression has been extensively studied in human endomet-
rium (Aplin et al., 1994, 1998; DeLoia et al., 1998; Horne et al., 2005;
Wang et al., 2008); however, there is limited information available on
MUC4 and MUC16 expression in human uterine tissues. Studies from
Gipson and colleagues demonstrate MUC16 (CA-125) expression at
the apical surface of luminal epithelia with little change during the men-
strual cycle (Gipson et al., 2008), in contrast to changing patterns
observed for MUC1 (Hey et al., 1994). Recently, serological studies indi-
cated that CA 125 levels are useful markers of endometriosis (Patrelli
et al., 2011; Socolov et al., 2011; Szubert et al., 2012). Genetic poly-
morphisms in MUC4 are associated with endometriosis in certain popu-
lations (Chang et al., 2011), but little information on protein and mRNA
expression is available. An isolated report has shown MUC4 expression
by immunostaining of secretory stage samples from women in the secre-
tory stage of the cycle and undergoing in vitro fertilization (IVF) (Koscinski
et al., 2006). However, careful comparative studies of the expression of
these three major membrane-tethered mucins have not been performed
in the cycling endometrium and endometriosis.
In the current study, we report a comprehensive expression profile
of MUC1, MUC4 and MUC16 in normal endometrium during the men-
strual cycle and in eutopic and ectopic endometrium of women with and
without endometriosis. Mucin expression profile studies so far have been
performed relative to the housekeeping gene, b-actin (ACTB). Here, we
use the epithelial-specific markers, cytokeratin-18 mRNA (KRT18) or pan-
cytokeratin antibodies, as controls for changes in the content of the uterine
epithelial population that occur during the menstrual cycle (Moll, 1983).
Materials and Methods
Sample collection
All patient samples were collected according to the Institutional Review
Board for Baylor College of Medicine and affiliated hospitals, Greenville Hos-
pital System and University of North Carolina School of Medicine and pro-
cessed at Rice University with approval from the Institutional Review
Board at Rice University. Sample collection was performed as described pre-
viously (Hawkins et al., 2011; Plante et al., 2012). All tissue samples were col-
lected with patient consent and approvals from the Institutional Review
Board for Baylor College of Medicine and affiliated hospitals, Greenville Hos-
pital System and University of North Carolina School of Medicine and pro-
cessed at Rice University with approval from the Institutional Review
Board at Rice University. Tissue collection was performed as described pre-
viously (Hawkins et al., 2011; Plante et al., 2012). Normal endometrium
tissue samples from S.L.Y. (Plante et al., 2012) were obtained from a tissue
library, with participants’ cycles ranging from 25 to 35 days. Samples were
randomized to a specific proliferative cycle day or a specific day post-
luteinizing hormone (LH) surge. Endometrial histology and dating was per-
formed according to Noyes criteria (Noyes et al., 1950). Matched samples of
endometrium and endometriosis obtained were not LH timed but confirmed
histologically according to Noyes criteria (Noyes et al., 1950). Samples were
categorized as proliferative (n¼ 6), early secretory (n¼ 4), mid-secretory
(n¼ 6) and late secretory (n¼ 4), and stage-matched eutopic and ectopic
endometrial samples (total n¼ 6; early secretory, stages I-II, n¼ 1; secretory,
stage II, n¼ 3; proliferative, stage II, n¼ 1; mid-secretory, stage III, n¼ 1).
For the purpose of immunohistochemistry, samples from normal secretory
endometrium, and proliferative and mid-secretory endometriosis grade stage
II were used. These samples obtained from S.M.H. (Hawkins et al., 2011)
were from women with regular menstrual cycles,whowere free fromhormones
for at least 30 days before surgery. Menstrual cycle phase was determined by
patient-provided information and confirmed by pathology according to standard
criteria (Noyes et al., 1950). Samples were categorized as non-endometriosis
proliferative (n¼ 5), non-endometriosis secretory (n¼ 6) and endometriotic
samples (total n ¼ 6; proliferative, n ¼ 2; secretory, n ¼ 2; interval phase,
n ¼ 1; inactive phase, n ¼ 1).
RNA isolation, DNAse treatment and
qRT–PCR
Total RNA was isolated as described (Hawkins et al., 2011; Plante et al.,
2012). RNA was diluted with nuclease free water to a volume of 40 ml and
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DNAse treated (Ambion, Austin, TX, USA; AM1906) according to the man-
ufacturer’s instructions. Reverse transcriptase reactions were performed
using 1 mg of total RNA in a 20 ml reaction using qScript cDNA Super mix
(Quanta; 95048) incubated for 5 min at 258C, 30 min at 428C and 5 min at
858C. Real-time PCR was performed using the primer sequences shown in
Table I and SYBR Green Super mix (Quanta Bioscience). Samples were
cycled for 30 s at 958C, 30 s at 598C and 30 s for 728C for 40 cycles for
MUC1, MUC16, KRT18 and ACTB. For MUC4, and for accompanying
KRT18, samples were cycled for 30 s at 958C, 15 s at 588C and 15 s for
728C for 40 cycles. The relative amounts of mucin mRNA were identified
using the comparative threshold cycle method and normalized to that of
either KRT18 or ACTB. Primer sets not previously described were designed
using Primer-BLAST (NCBI) and were validated according to protocols in
the BioRad CFX96 manual.
Immunofluorescence analysis
Frozen sections from mid-secretory stage of cycling endometrium were
thawed at room temperature for 20 min, rehydrated with 1× PBS for
10 min and fixed with 4% (wt/vol) paraformaldehyde for 10 min. Slides
were washed three times for 10 min each with 1× PBS, blocked for 1 h
with [1% (wt/vol) BSA in PBS] and washed three times with 1× PBS.
Primary antibody was added and incubated overnight at the indicated dilu-
tions: rabbit polyclonal antibody to wide spectrum cytokeratin, 1:50
(Abcam; ab9377); mouse monoclonal anti-MUC4, 1:250 (kindly provided
by Dr S.K. Batra, University of Nebraska); rabbit anti-MUC1, 1:50 (CT-1,
ref.); mouse monoclonal anti-MUC16 (OC125), 1:200 (kindly provided
by Dr Robert Bast, MD Anderson Cancer Center). Mouse and rabbit IgG
controls (Jackson ImmunoResearch Laboratories) at 250 ng each as well as
a secondary antibody only were used as controls. Slides were washed
three times for 10 min each with 1× PBS, then incubated with 1:400 dilution
of secondary antibody, Alexa-fluor 647 goat anti-mouse (Invitrogen;
A21235) or Alexa-fluor 488 goat anti-rabbit (Invitrogen; A11034) in 1%
(wt/vol) BSA in PBS for 1 h in the dark, and washed three times for 10 min
with 1× PBS. Samples were mounted with Prolong-Antifade with DAPI as
per manufacturer’s instructions (Invitrogen) and subjected to analyses by
confocal microscopy (LSM710).
Tissue samples from proliferative stage endometriosis were embedded in
O.C.T. and stored at 2808C. Tissue blocks were incubated at 2208C over-
night prior to sectioning in a Leica cryotome. Ten micron tissue sections were
then processed as described above. Tissue sections were imaged using a
Nikon A1-Rsi confocal microscope.
The pancreatic adenocarcinoma cell line, HPAF was plated in an 8-well
chamber slide in RPMI + 10% (vol/vol) FBS until confluent. Cells were
fixed in 4% (vol/vol) paraformaldehyde for 10 min, then in 0.02%
(vol/vol) Triton X-100 for 2 min. Cells were blocked in filtered 3%
(wt/vol) BSA for 1 h, followed by overnight incubation at 48C with
MUC4 antibody (8G7 from Dr Batra) at a 1:100 dilution in filtered 3%
(wt/vol) BSA. Cells were washed three times for 5 min each in PBS,
and then incubated with goat anti-mouse AlexaFluor 647 at a dilution
of 1:400 in filtered 3% (wt/vol) BSA for 1 h at room temperature, fol-
lowed by two 5 min washes in PBS. Cells were then washed in PBS +
DAPI for 5 min. Coverslips were mounted using ProLong Gold anti-fade
agent and cells were imaged on a Zeiss LSM 710 confocal microscope
(Supplementary data, Fig. S1).
Statistical analysis
Statistical analyses were performed using a two-tailed student’s t-test
(GraphPad InStat program; GraphPad Software, Inc., San Diego, CA, USA).
Results
Mucin mRNA profiles in normal endometrium
across the menstrual cycle
Levels of MUC1 and MUC16 mRNAs have been previously profiled
in human endometrial tissues (Hey et al., 1994; Gipson et al., 1997,
2008; Hebbar et al., 2005). These studies did not account for variations
in uterine epithelial cell populations during the menstrual cycle. We
therefore examined mucin mRNA expression levels by qRT–PCR in the
different stages of the cycling endometrium relative to the epithelial
marker, cytokeratin-18, KRT18 (Fig. 1). The mucins, MUC1, MUC4 and
MUC16, were expressed in all stages of the cycle with very low expression
of MUC4 detected in all cases. Therewas no significant change in MUC1 and
MUC16 mRNA expression across the cycle when compared with KRT18.
Since this was in apparent conflict with previous reports, we also compared
MUC1 and MUC16 expression relative to ACTB used by others as a load
control in similar studies. In agreement with previous reports (Hey et al.,
1994; Gipson et al., 2008), we observed a rise in MUC1 and MUC16
mRNA expression relative to ACTB during the secretory phase; however,
no significant changes were observed in the expression of these mucin
mRNAs relative to KRT18 (Fig. 2A and B, respectively). Thus, the appar-
ent rise in MUC1 and MUC16 reported previously parallels the increased
epithelial content of the endometrium during the secretory phase.
Mucin mRNA profiles in normal endometrium
and endometrium of women with
endometriosis
Mucin glycoproteins have been assessed as potential biomarkers or
diagnostic tools in endometriosis because of their utility as markers of
.............................................................................................................................................................................................
Table I Oligonucleotide primer sequences used in this study.
Gene Forward Reverse Amplicon Reference
MUC1 5′ AGAGAAGTTCAGTGCCCAGC 5′ TGACATCCTGTCCCTGAGTG 114 bp Dharmaraj et al. (2010)
MUC4 5′ GCCCAAGCTACAGTGTGACTC 5′ ATGGTGCCGTTGTAATTTGTT 102 bp Argueso et al. (2002)
MUC4-CT 5′ CCATGGAGGCCAGTGCCAGC 5′ GTGCTCACAGTGCTCGCCCC 94 bp aThis Paper
MUC16 5′ GCCTCTACCTTAACGGTTACAATGAA 5′ GGTACCCCATGGCTGTTGTG 114 bp Argueso et al. (2003)
ACTB 5′ GATGAGATTGGCATGGCTTT 5′ CACCTTCACCGGTCCAGTTT 100 bp Dharmaraj et al. (2010)
KRT18 5′ GACACCAATATCACACGACTG 5′ GGCTTGTAGGCCTTTTACTTC 108 bp aThis Paper
aRefer to materials and methods for primer validation.
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Figure 1 Mucin mRNA profile in normal endometrium. Box plots were used to express levels of transmembrane mucin mRNA levels in the cycling human
endometrium. Mucin mRNA expression was determined relative to that of epithelial marker, cytokeratin-18 (KRT18) by qRT–PCR as described in Materials
and Methods. Mucins were expressed at similar levels at all stages of the cycle with very low expression of MUC4. The box plot shades the second and third
quartilesof thedata.Theblack line in thebox isdrawnat themedianvalue.Thewhiskersaboveandbelowshowthemaximumandminimumvalues, respectively.
Figure 2 Mucin mRNA levels relative to those of KRT18 (A) and ACTB (B). MUC1, MUC16, KRT18 and ACTB mRNA levels were determined by qRT–
PCR as described in Materials and Methods. Box plots were used to express these data as described in the legend to Fig. 1. No significant differences in mucin
expression were observed across the cycle when compared with KRT18 mRNA levels.
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malignant diseases (Mayet al., 2010). We sought to profile MUC1, MUC4
and MUC16 mRNA expression in normal endometrium and in endomet-
rium of women with endometriosis again relative to the epithelial
marker, KRT18 mRNA. MUC1 and MUC16 mRNA expression did not
vary significantly between these conditions (Fig. 3). MUC4 mRNA was
much more difficult to detect than MUC1 and MUC16 in normal endo-
metrium and in endometrium from endometriosis patients (Fig. 3).
Primers to the cytoplasmic tail (CT) region of the MUC4 gene were
therefore designed, in addition to the primers to the tandem repeat
(TR) region, to detect MUC4 mRNA expression to account for any vari-
ability in MUC4 mRNA expression (Table I). We confirmed minimal
levels of MUC4 mRNA expression in both normal endometrium and
that of women with endometriosis (Fig. 4). Collectively, these data indi-
cated little variation in MUC1, MUC4 and MUC16 mRNA expression in
the eutopic endometrium of women with endometriosis when com-
pared with normal endometrium.
Mucin mRNA profiles in stage-matched
endometriotic tissue
We then sought to compare mucin expression in stage-matched eutopic
and ectopic samples from endometriosis patients relative to KRT18
mRNA (Fig. 5). qRT–PCR analyses revealed that MUC1 (Fig. 5A),
MUC4 (Fig. 5B) and MUC16 (Fig. 5C) mRNA expression did not vary
between eutopic and ectopic stage-matched endometriotic tissues.
MUC4 mRNA expression was not significantly higher in ectopic endome-
triotic tissue (Fig. 5B) and was still very low relative to that of MUC1 and
MUC16. Collectively, these results were in accordance with the above
experiment and showed little variation in mucin expression in stage-
matched eutopic and ectopic endometriotic tissue.
Transmembrane mucin protein detection by
immunohistochemistry
To determine the localization of each mucin, immunohistochemistry was
performed on frozen sections from normal and mid-secretory endomet-
riosis grade Stage II endometrium (Fig. 6A–L). Robust MUC1 and
MUC16 localization was confirmed on the apical surface of epithelia
(Fig. 6A–D). Localization of MUC16 protein expression to epithelia
was confirmed using the pan-cytokeratin antibody (Fig. 6I–L). We per-
formed immunohistochemistry for MUC4 only in endometrium from
endometriosis patients since MUC4 mRNA expression was barely de-
tectable in normal cycling endometrium. Confirming the results from
MUC4 qRT–PCR analyses, a lack of reactivity with the MUC4-specific
antibody was observed in sections of mid-secretory endometriotic
tissue (Fig. 6E–H). Pan-cytokeratin staining was performed to identify
epithelial cells in each case (Fig. 6F and J). MUC4 immunohistochemistry
on frozen sections from proliferative stage endometrium from endomet-
riosis patients was also performed (Supplementary data, Fig. S1). Similar
to the results obtained in mid-secretory endometriosis grade tissues,
MUC4 protein expression was undetectable (Supplementary data, Fig.
S1B) while MUC1 and MUC16 were expressed (Supplementary data,
Fig. S1A). Recognition of MUC4 by the 8G7 antibody was confirmed
by positive immunostaining for MUC4 in the pancreatic adenocarcinoma
cell line, HPAF (Supplementary data, Fig. S1C and D). Collectively, these
data confirm that MUC1 and MUC16 expression are restricted to endo-
metrial epithelial cells and that MUC4 protein is not present at appre-
ciable levels in endometriosis.
Discussion
Mucin expression and distribution changes in several gynecological path-
ologies, including endometrial cancer and endometriosis (He et al.,
Figure 3 Relative abundance of mucin mRNAs in normal endomet-
rium and in endometrium of women with endometriosis. MUC1,
MUC4 and MUC16 mRNA in normal endometria at different stages of
the menstrual cycle and in endometria of women with endometriosis
relative to KRT18 mRNA were determined as described in Materials
and Methods. Box plots were used to express the data as described in
the legend to Fig. 1. No significant differences were observed
between these conditions.
Figure 4 A comparison of MUC4 mRNA detection by primers
against tandem repeat (TR) and cytoplasmic tail (CT) regions of the
MUC4 gene. MUC4 mRNA in normal endometria at different stages
of the menstrual cycle and in endometria of women with endometriosis
relative to KRT18 mRNA using primers to the TR and CT regions. Box
plots were used to express these data as described in the legend to Fig. 1.
No significant differences were observed using either set of primers.
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2011). Endometriosis is a prevalent endocrine-driven disease occurring
in almost 45% of all women receiving laparoscopic examination and in
10% of all women presenting with clinical symptoms (Lessey, 2000;
Winkel, 2003; de Ziegler et al., 2010). Symptoms range from mild to
severe pelvic pain and infertility (Winkel 2003; de Ziegler et al., 2010)
and are cyclical following the rise and fall of ovarian steroid hormones
through the menstrual cycle that act on endometriotic tissue as well as
the endometrium (Winkel, 2003). The etiology of endometriosis
remains unclear, but a common theory is that retrograde menstruation
leads to the deposition of endometrial tissue on the ovaries and within
the peritoneal cavity. Retrograde menstruation is common in menstruat-
ing women, but the reasons that some women get endometriosis and
others do not remain an area of active investigation.
The current study focused on quantitative analyses of membrane-
tethered mucin (MUC1, MUC4 and MUC16) expression in normal
endometrium and eutopic and ectopic endometrium of endometriosis
patients. This is the first comprehensive study of these three key
membrane-associated mucins in these contexts. Only three reports
have examined MUC4 expression by immunohistochemistry in human
endometrium (Gipson et al., 1997; Koscinski et al., 2006; Alameda
et al., 2007) with no agreement on the expression pattern of MUC4.
Gipson et al. (1997) reported a lackof MUC4 expression in normal endo-
metrium while Koscinski et al. (2006) report isolated patches of MUC4
expressed in luminal and glandular epithelium using the same 8G7
antibody utilized in the present studies in infertile and women undergoing
IVF. A lack of information on MUC4-specific antibody used by Alameda
et al. (2007) hinders interpretation of their results which indicate endo-
metrial MUC4 protein expression in a subset of women. There also is
limited information on MUC16 expression in the cycling endometrium,
although qRT–PCR has been used to assess levels of MUC16 mRNA
levels during the cycle (Gipson et al., 2008). Previous reports have indi-
cated that MUC1 and MUC16 vary in the cycling endometrium with
maximal expression in the secretory phase (Hey et al., 1994; Gipson
et al., 2008). These studies relied on the use of ACTB or 28S RNA as
RNA load controls, i.e. an RNA species found in all endometrial cells.
When MUC1 and MUC16 mRNA levels were compared relative to
ACTB mRNA, our results were in agreement with previous reports
(Hey et al., 1994; Gipson et al., 2008).
We used KRT18 mRNA as a control for potential changes in the
epithelial populations in endometrial samples (Moll, 1983). Our data
indicate that endometrial MUC1 and MUC16 mRNA expression does
not change significantly relative to KRT18 and rather seems to vary in par-
allel with the changes in the epithelial populations in the endometrium.
While it is possible that KRT18 is hormonally regulated, this has not
been described. A number of agents including progesterone and proin-
flammatory cytokines modulate transmembrane mucin expression in
uterine cell types and endometrium of various animal models (Hoffman
et al., 1998; Brayman et al., 2006, 2007; Dharmaraj et al., 2010). Nonethe-
less, the current studies indicate that changes in mucin expression are not
observed during the normal menstrual cycle nor in endometriotic tissues.
Several reports also indicate that serum MUC1 levels are not changed in
endometriosis (reviewed in May et al. 2010). One report describes a re-
duction of MUC1 in endometriosis (Margarit et al. 2010). Endometriosis
has been suggested as a precursor for ovarian cancer (Worley et al.,
2013) and the serum MUC16 levels test (detected as CA-125) is a
widely used test for ovarian cancer. Elevated serum MUC16/CA-125
has also been used as a marker for endometriosis, particularly for Stage
III–IV disease (Mol et al., 1998; Vodolazkaia et al., 2012). Our data indicate
that MUC16 mRNA expression does not vary in endometriotic tissue
through the cycle relative to the levels observed in normal endometrium.
Nonetheless, our samples were primarily obtained from patients present-
ing with stage I–II endometriosis and thus we can only support the notion
that MUC16/CA 125 is not a useful marker for early-stage disease.
Previous reports have examined MUC4 expression in the human
endometrium (Gipson et al., 1997; Koscinski et al., 2006; Alameda
Figure 5 (A) MUC1, (B) MUC4 and (C) MUC16 mRNA expression
in stage-matched eutopic and ectopic endometria of endometriosis
patients. Six menstrual stage-matched samples, either from secretory
or proliferative stage of the menstrual cycle and stage II or III (one
sample) endometriosis were analyzed by qRT–PCR for the different
mucins as described in Materials and Methods. Box plots were used
to express these data as described in the legend to Fig. 1. Changes in
levels of MUC4 expression was observed in endometriotic tissue
when compared with eutopic endometriotic tissue.
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et al., 2007). Using an established qRT–PCR protocol that detects a
region of MUC4 mRNA encoding a portion of the ectodomain, we
found that MUC4 mRNA expression is at very low levels under all con-
ditions examined. Consistent with this, MUC4 protein was undetectable
by immunohistochemistry in proliferative and mid-secretory stage endo-
metriosis. Thus, we conclude that full-length MUC4 is not expressed at
appreciable levels in normal endometrium and endometriosis. Although
we found a trend toward higher MUC4 mRNA levels in ectopic versus
eutopic endometrium of stage-matched endometriosis patients, this
change was not significant. It would be interesting to determine whether
a significant accumulation of MUC4 expression occurs in advanced
stages of endometriosis.
Progesterone resistance is now considered a key player in the etiology
of endometriosis (Brosens et al., 2012). Nuclear receptors and nuclear
receptor coregulator dysregulation are associated with the progression
of endometriosis either due to an increase in estrogen or due to signaling
by inflammatory molecules (Han and O’Malley, 2014). Several of these
factors, such as PR-A and PR-B, PPARg and TNFa regulate the expres-
sion of transmembrane mucins in various systems (Brayman et al., 2006;
Dharmaraj et al., 2010; Wang et al., 2010; Morgado and Carson, unpub-
lished observations). Thus, an understanding of mucins in endometriosis
is important. There is great need for endometriosis biomarkers to aid
clinical diagnosis and also to monitor the disease. Changes in mucin
glycoforms have been suggested to characterize endometrial disease
(Sivridis et al., 2002; Seeber et al., 2008). Although we have found no
alterations in mucin expression in endometriosis, a comprehensive
profile of transmembrane mucin expression, including changes in the
oligosaccharide moieties carried by the mucin core proteins, in normal
and endometriotic tissues may yet allow for development of meaningful
biomarkers. In addition, changes in the oligosaccharide structurescarried
by mucins may have important biological consequences such as binding
of selectins (Carson et al., 2006) or suppression of the immune system
(Daniels et al., 2002; Hauselmann and Borsig, 2014). Future studies
should focus on how glycoforms of MUC1 and MUC16 change in endo-
metrial disease states in ways that might promote disease progression.
Supplementary data
Supplementary data areavailable athttp://humrep.oxfordjournals.org/.
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